183 related articles for article (PubMed ID: 34080094)
1. Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial.
Hagiwara Y; Sawaki M; Uemura Y; Kawahara T; Shimozuma K; Ohashi Y; Takahashi M; Saito T; Baba S; Kobayashi K; Mukai H; Taira N
Breast Cancer Res Treat; 2021 Aug; 188(3):675-683. PubMed ID: 34080094
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
4. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
5. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
6. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
7. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
Harbeck N; Huang CS; Hurvitz S; Yeh DC; Shao Z; Im SA; Jung KH; Shen K; Ro J; Jassem J; Zhang Q; Im YH; Wojtukiewicz M; Sun Q; Chen SC; Goeldner RG; Uttenreuther-Fischer M; Xu B; Piccart-Gebhart M;
Lancet Oncol; 2016 Mar; 17(3):357-366. PubMed ID: 26822398
[TBL] [Abstract][Full Text] [Related]
8. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
Stebbing J; Baranau Y; Baryash V; Manikhas A; Moiseyenko V; Dzagnidze G; Zhavrid E; Boliukh D; Stroyakovskii D; Pikiel J; Eniu A; Komov D; Morar-Bolba G; Li RK; Rusyn A; Lee SJ; Lee SY; Esteva FJ
Lancet Oncol; 2017 Jul; 18(7):917-928. PubMed ID: 28592386
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study.
Sawaki M; Taira N; Uemura Y; Saito T; Baba S; Kobayashi K; Kawashima H; Tsuneizumi M; Sagawa N; Bando H; Takahashi M; Yamaguchi M; Takashima T; Nakayama T; Kashiwaba M; Mizuno T; Yamamoto Y; Iwata H; Toyama T; Tsugawa K; Kawahara T; Mukai H;
Breast; 2022 Dec; 66():245-254. PubMed ID: 36371994
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
[TBL] [Abstract][Full Text] [Related]
11. Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients.
Sawaki M; Taira N; Uemura Y; Saito T; Baba S; Kobayashi K; Kawashima H; Tsuneizumi M; Sagawa N; Bando H; Takahashi M; Yamaguchi M; Takashima T; Nakayama T; Kashiwaba M; Mizuno T; Yamamoto Y; Iwata H; Kawahara T; Ohashi Y; Mukai H;
J Clin Oncol; 2020 Nov; 38(32):3743-3752. PubMed ID: 32936713
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial.
Papakonstantinou A; Matikas A; Bengtsson NO; Malmström P; Hedayati E; Steger G; Untch M; Hübbert L; Johansson H; Hellström M; Gnant M; Loibl S; Greil R; Moebus V; Foukakis T; Bergh J
Cancer; 2020 Mar; 126(6):1175-1182. PubMed ID: 31851385
[TBL] [Abstract][Full Text] [Related]
13. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.
Fehrenbacher L; Cecchini RS; Geyer CE; Rastogi P; Costantino JP; Atkins JN; Crown JP; Polikoff J; Boileau JF; Provencher L; Stokoe C; Moore TD; Robidoux A; Flynn PJ; Borges VF; Albain KS; Swain SM; Paik S; Mamounas EP; Wolmark N
J Clin Oncol; 2020 Feb; 38(5):444-453. PubMed ID: 31821109
[TBL] [Abstract][Full Text] [Related]
14. Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer.
Taira N; Sawaki M; Uemura Y; Saito T; Baba S; Kobayashi K; Kawashima H; Tsuneizumi M; Sagawa N; Bando H; Takahashi M; Yamaguchi M; Takashima T; Nakayama T; Kashiwaba M; Mizuno T; Yamamoto Y; Iwata H; Ohashi Y; Mukai H; Kawahara T;
J Clin Oncol; 2021 Aug; 39(22):2452-2462. PubMed ID: 33835842
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
[TBL] [Abstract][Full Text] [Related]
17. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
Dang C; Guo H; Najita J; Yardley D; Marcom K; Albain K; Rugo H; Miller K; Ellis M; Shapira I; Wolff AC; Carey LA; Moy B; Groarke J; Moslehi J; Krop I; Burstein HJ; Hudis C; Winer EP; Tolaney SM
JAMA Oncol; 2016 Jan; 2(1):29-36. PubMed ID: 26539793
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
19. Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.
Dieci MV; Conte P; Bisagni G; Brandes AA; Frassoldati A; Cavanna L; Musolino A; Giotta F; Rimanti A; Garrone O; Bertone E; Cagossi K; Sarti S; Ferro A; Piacentini F; Maiorana A; Orvieto E; Sanders M; Miglietta F; Balduzzi S; D'Amico R; Guarneri V
Ann Oncol; 2019 Mar; 30(3):418-423. PubMed ID: 30657852
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)].
Sawaki M; Tokudome N; Mizuno T; Nakayama T; Taira N; Bando H; Murakami S; Yamamoto Y; Kashiwaba M; Iwata H; Uemura Y; Ohashi Y
Jpn J Clin Oncol; 2011 May; 41(5):709-12. PubMed ID: 21355003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
